RSS
2 Nov 2020

Janssen Submits Paliperidone Palmitate 6-Month (PP6M) Supplemental New Drug Application to U.S. FDA for Treatment of Schizophrenia in Adults

Author: admintech | Filed under: Press Release

TITUSVILLE, N.J., Nov. 2, 2020 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for paliperidone palmitate 6-month (PP6M) for the…

This entry was posted on Monday, November 2nd, 2020 at 7:27 am and is filed under Press Release. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

«

»